Finch Therapeutics Ownership
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Finch |
Finch Pink Sheet Ownership Analysis
About 53.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. Finch Therapeutics recorded a loss per share of 6.59. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 12th of June 2023. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.The quote for Finch Therapeutics Group is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Finch Therapeutics Group call Mark Smith at 617 229 6499 or check out https://www.finchtherapeutics.com.Finch Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Finch Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Finch Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Finch Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smisek Jeffery A over six months ago Disposition of 3750 shares by Smisek Jeffery A of Finch Therapeutics subject to Rule 16b-3 | ||
Graf Susan E over six months ago Acquisition by Graf Susan E of 44843 shares of Finch Therapeutics subject to Rule 16b-3 | ||
Smisek Jeffery A over six months ago Disposition of 6642 shares by Smisek Jeffery A of Finch Therapeutics at 2.57 subject to Rule 16b-3 | ||
Smisek Jeffery A over a year ago Sale by Smisek Jeffery A of 1470 shares of Finch Therapeutics | ||
Blischak Matthew P over a year ago Acquisition by Blischak Matthew P of 962899 shares of Finch Therapeutics subject to Rule 16b-3 | ||
Blaustein Marc over a year ago Sale by Blaustein Marc of 4619 shares of Finch Therapeutics |
Finch Therapeutics Outstanding Bonds
Finch Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Finch Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Finch bonds can be classified according to their maturity, which is the date when Finch Therapeutics Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Currently Active Assets on Macroaxis
| NVDA | NVIDIA | |
| CRESY | Cresud SACIF y | |
| GOOG | Alphabet Inc Class C | |
| FMC | FMC Corporation | |
| XYF | X Financial Class |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |